ArticleInternational journal of ophthalmology2026
Improving the post-oculoplastic tear film: trehalose as a critical adjunct.
Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the comparative effects of a combined trehalose-sodium hyaluronate (TD) formulation versus sodium hyaluronate (SH) monotherapy on postoperative ocular surface recovery following eyelid surgery, with additional analysis across surgical subgroups.
methodsThis retrospective comparative study included patients who underwent eyelid surgery for ectropion, entropion, or eyelid reconstruction between August 2021 and July 2024. Patients were divided into two treatment groups based on the postoperative tear substitutes used: Group SH treated with 0.15% SH eye drops, and Group TD treated with a combination of 3% trehalose and 0.15% SH. Postoperatively, patients received either 0.15% SH alone or a combination of 3% trehalose and 0.15% SH four times daily for 3mo. Ocular surface parameters-including tear break-up time (TBUT), Ocular Surface Disease Index (OSDI), Oxford staining score, meibomian gland loss (MGL), and central corneal epithelial thickness (CCET)-were assessed at baseline and 3mo. Subgroup analyses were performed by surgical indication.
resultsA total of 114 patients were included in the study (mean age: 70.3±12.1y; 25 females). Group SH comprised 57 patients (15 females, mean age: 69.2±11.4y), while the Group TD also included 57 patients (10 females, mean age: 71.5±12.8y). Both groups showed significant improvement across all parameters; however, the TD group demonstrated superior outcomes in TBUT (mean difference: +0.77s, 95%CI: 0.12-1.42,
conclusionThis study is the first to comparatively assess trehalose-based tear supplementation across distinct oculoplastic surgery subgroups. The combination of TD significantly enhanced postoperative ocular surface parameters-especially in complex reconstructive settings-compared to SH alone. These findings highlight the potential of tailored, antioxidative tear film strategies in optimizing recovery after eyelid surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.